Literature DB >> 12942578

Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms.

Igor B Rosenwald1, Songtao Wang, Lou Savas, Bruce Woda, James Pullman.   

Abstract

BACKGROUND: Stimulation of resting cells by growth factors leads to an increase in the rate of protein synthesis, which is necessary for cell growth and division. Translation initiation factor eIF-2alpha is one of the key translation factors mediating the effects of growth factors on protein synthesis. In normal cells, expression of eIF-2alpha is increased transiently, but its levels are elevated constitutively in oncogene-transformed cells. Overexpression of constitutively active eIF-2alpha in rodent cells makes them tumorigenic. In this article, the authors report their findings on the increased expression of eIF-2alpha in human benign and malignant neoplasms originating from melanocytes and colonic epithelium.
METHODS: Immunohistochemistry was used to analyze the expression of eIF-2alpha, eIF-4E, and cyclin D1 in melanocytic nevi and melanomas and the expression of eIF-2alpha in colonic adenomas and carcinomas.
RESULTS: The authors found that the expression of eIF-2alpha was increased markedly in both benign and malignant neoplasms of melanocytes and colonic epithelium.
CONCLUSIONS: Increased expression of eIF-2alpha took place in both benign and malignant neoplasms of melanocytes and colonic epithelium. These findings suggest that elevated expression of this translation initiation factor may contribute to tumor initiation and progression but that it is not sufficient for establishing a malignant phenotype in the tumors analyzed in this study. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942578     DOI: 10.1002/cncr.11619

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

2.  Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.

Authors:  Zeyu Xiong; Yan Yan; Enli Liu; Richard T Silver; Srdan Verstovsek; Fan Yang; Hong Wang; Josef Prchal; Xiao-Feng Yang
Journal:  Clin Immunol       Date:  2006-11-17       Impact factor: 3.969

Review 3.  Translational control in cancer.

Authors:  Deborah Silvera; Silvia C Formenti; Robert J Schneider
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

Review 4.  Translational Control in Cancer.

Authors:  Nathaniel Robichaud; Nahum Sonenberg; Davide Ruggero; Robert J Schneider
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-07-01       Impact factor: 10.005

Review 5.  Translational regulator eIF2α in tumor.

Authors:  Qiaoli Zheng; Jingjia Ye; Jiang Cao
Journal:  Tumour Biol       Date:  2014-03-09

6.  Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.

Authors:  Michael Jewer; Scott D Findlay; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2012-10-09       Impact factor: 5.782

7.  her-2 upstream open reading frame effects on the use of downstream initiation codons.

Authors:  Christina C Spevak; Eun-Hee Park; Adam P Geballe; Jerry Pelletier; Matthew S Sachs
Journal:  Biochem Biophys Res Commun       Date:  2006-10-02       Impact factor: 3.575

Review 8.  Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Authors:  Gregory R Kardos; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2015-09       Impact factor: 4.693

9.  Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells.

Authors:  Lixia Chen; Guoqing Tian; Changxia Shao; Everardo Cobos; Weimin Gao
Journal:  Mol Biol Rep       Date:  2009-10-15       Impact factor: 2.316

10.  Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target.

Authors:  Ting Chen; Duygu Ozel; Yuan Qiao; Fred Harbinski; Limo Chen; Séverine Denoyelle; Xiaoying He; Nela Zvereva; Jeffrey G Supko; Michael Chorev; Jose A Halperin; Bertal H Aktas
Journal:  Nat Chem Biol       Date:  2011-07-17       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.